Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Antibody-drug Conjugates, HER2-low Breas...
Phase Not Applicable
Enrollment 700
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include patient demographics, tumor characteristics, ADC regimens (e.g., trastuzumab deruxtecan, sacituzumab govitecan), treatment sequencing, survival outcomes, and safety profiles. Genomic data (e.g., HER2 expression dynamics, TROP2 levels) are integrated to explore resistance mechanisms and prognostic biomarkers.mechanisms. This study aims to investigate the efficacy of different ADC sequential regimens in HER2-low breast cancer patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Other: Non-intervention research — Non-intervention research

Primary Outcomes

  • Progression-free survival (From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-01-01
Completion: 2026-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 700 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-sen University
Contact Information
Study Contact:
Yang Yalan, Bachelor
+8613826282096
yangylan7@mail2.sysu.edu.cn
Interventions
  • Other: Non-intervention research — Non-intervention research
Study Locations (1 sites)
Sun yat-sen University Cancer, Guangzhou, Guangdong 510060 China
Eligibility Criteria
Inclusion Criteria: * Diagnosed with HER2-low breast cancer, defined as immunohistochemistry (IHC) score of 1+ or IHC score of 2+ with negative in situ hybridization (FISH-negative) * Received sequential administration of two or more ADCs * Complete data for patient's character, laboratory and imaging test, treatment and follow-up are available. Exclusion Criteria: * Concomitant with other tumor components at the time of diagnosis; * Have a history of any other malignant tumors; * Lack of complete data

VS-6766+Abema+Fulv in Met HR+/HER- BC

NCT05608252
Recruiting
Conditions Breast Cancer, Hormone Receptor-positive...
Phase PHASE1, PHASE2
Enrollment 63
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: VS-6766 — Taken Orally
  • Drug: Abemaciclib — Taken Orally
  • Drug: Fulvestrant — Administered by intramuscular injection

Primary Outcomes

  • Phase 1 Maximum tolerated dose (MTD) (4 Weeks up to 2 years)
  • Phase 1 Recommended Phase II Dose (RP2D) (4 Weeks up to 2 years)
  • Phase 2 Clinical benefit rate (CBR) (6 months up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-02-23
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 63 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Adrienne G. Waks
Collaborators: Verastem, Inc., Eli Lilly and Company
Principal Investigators:
  • Adrienne G Waks, MD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Adrienne G Waks, MD
617-632-3800
Adrienne_waks@dfci.harvard.edu
Adrienne G Waks, MD
617-632-3800
awaks@partners.org
Brigham and Women's Hospital
Adrienne G Waks, MD
Brigham and Women's Hospital
Interventions
  • Drug: VS-6766 — Taken Orally
  • Drug: Abemaciclib — Taken Orally
  • Drug: Fulvestrant — Administered by intramuscular injection
Study Locations (3 sites)
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114 United States
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Dana Farber Cancer Institite, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically or cytologically confirmed hormone receptor positive (HR+), HER2 negative metastatic or locally recurrent unresectable invasive breast cancer. ER, PR and HER2 measurements should be performed according to institutional guidelines, in a CLIA-approved setting. Cut-off values for positive/negative staining should be in accordance with current ASCO/CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines. * Participants may have measurable or non-measurable disease according to RECIST v1.1. * Men and pre- and postmenopausal women are eligible. Ongoing monthly GNRH agonist is required in pre-menopausal women or male participants for at least 4 weeks prior to study entry. If men or pre-menopausal women have not received regular GNRH agonist for at least 4 weeks prior to study entry, these patients will be excluded. * Participants must have radiological or objective evidence of progression on any CDK 4/6 inhibitor-containing regimen in the metastatic setting, and/or relapse/progression during or within 12 months of completion of any CDK4/6 inhibitor-containing regimen in the adjuvant setting. * It is not mandatory to have a CDK4/6 inhibitor-containing regimen as the most recent treatment. * Participants must have radiological or objective evidence of progression on fulvestrant (as a single agent or as a component of any multi-drug regimen) in the metastatic setting. * It is not mandatory to have a fulvestrant-containing regimen as the most recent treatment. * Prior therapy: * No more than two prior chemotherapy regimens in the metastatic setting. * For both the phase I and phase II portions of this trial, there is no limit on prior lines of endocrine therapy in the adjuvant or metastatic setting. * For phase 2 cohort only: Willing to undergo pre- and on-treatment tumor biopsies. Patients are exempt from this requirement if, in the opinion of the investigator, the biopsy procedure would pose a significant risk. Biopsies are optional in the phase 1 cohort. * ECOG performance status \<2. * Participants must have normal organ and marrow function as defined below: * absolute neutrophil count ≥ 1.5 x 109/L * platelets ≥100,000/μl * hemoglobin ≥9 g/dL (If red blood cell transfusion has been administered, hemoglobin must remain stable and ≥9 g/dL without further transfusion for at least 1 week prior to first dose of study therapy). * total bilirubin ≤1.5mg/dL (≤3.0mg/dL in patients with known Gilbert syndrome and direct bilirubin within normal limits) * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN. * Adequate renal function with a creatinine clearance rate of ≥ 50 mL/min as calculated by the Cockcroft-Gault formula. * International normalized ratio (INR) ≤ 1.5 and partial thromboplastin time (PTT) ≤ 1.5 x ULN in the absence of anticoagulation or therapeutic levels in the presence of anticoagulation. * Creatine phosphokinase (CPK) ≤ 2.5 x ULN. * Adequate cardiac function with left ventricular ejection fraction ≥ 50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan. * Baseline QTc interval \< 480 ms (average of triplicate readings) using Fredericia's QT correction formula. NOTE: This criterion does not apply to patients with a complete or incomplete right or left bundle branch block. * Adequate recovery from toxicities related to prior systemic treatments, surgery, or radiotherapy to at least Grade 1 by CTCAE v 5.0. Exceptions include alopecia and peripheral neuropathy grade ≤ 2. * Age \>18 years. Because no dosing or adverse event data are currently available on the use of study agents in participants \<18 years of age, children are excluded from this study. * Women of childbearing potential, women who are made postmenopausal through use of GNRH agonists, and men must agree to use adequate contraception for the duration of protocol treatment. Women meeting these criteria will need to use adequate contraception for at least 30 days after the last dose of abemaciclib or VS-6766 and for one year after the last dose of fulvestrant. Men will need to use adequate contraception for 90 days after the last dose of abemaciclib or VS-6766 and for one year after the last dose of fulvestrant. Additionally, males must agree not to donate sperm for the duration of protocol treatment and for at least 90 days after the last dose of protocol therapy. Childbearing potential for this purpose is defined as: those who have not been surgically sterilized and/or have had a menstrual period in the past 12 months. Adequate contraception is defined as one highly effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by the participant and/or partner: Highly Effective Non-Hormonal Contraception Methods of birth control which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly are considered highly-effective forms of contraception. The following non-hormonal methods of contraception are acceptable: * True abstinence when this is in line with the preferred and usual lifestyle of the participant. \[Periodic abstinence (e.g., calendar, ovulation, symptothermal post-ovulation methods) and withdrawal are not acceptable methods of contraception\]. * Male sterilization (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). For female participants, the vasectomized male partner should be the sole partner. OR Effective Non-Hormonal Contraception Alternatively two of the following effective forms of contraception may be used instead: * Placement of non-hormonal or progesterone-coated intrauterine device (IUD) or intrauterine system (IUS). Consideration should be given to the type of device being used, as there are higher failure rates quoted for certain types, e.g., steel or copper wire. * Condom with spermicidal foam/gel/film/cream/suppository. * Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. * The use of barrier contraceptives should always be supplemented with the use of spermicide. The following should be noted: * Failure rates indicate that, when used alone, the diaphragm and condom are not highly effective forms of contraception. Therefore, the use of additional spermicides does confer additional theoretical contraceptive protection. * However, spermicides alone are ineffective at preventing pregnancy when the whole ejaculate is spilled. Therefore, spermicides are not a barrier method of contraception and should not be used alone. It should be noted that two forms of effective contraception are required. A double barrier method is acceptable, which is defined as condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. * A female of childbearing potential, as defined above in section 3.1.12, must have a negative serum pregnancy test performed within 7 days of C1D1. A positive urine test must be confirmed by a serum test. Pregnancy testing does not need to be pursued in female participants who are: * Age \>60 years; or * Age \<60 years with intact uterus and amenorrhea for 12 consecutive months or more AND estrogen (estradiol) levels within postmenopausal range; or * Status post bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation * Participant must be able to swallow and retain oral medication. * Ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * Participants with active brain metastases or with known carcinomatous meningitis. Stable, treated brain metastases are allowed (this includes participants who have documented radiologic stability at least 4 weeks after radiotherapy, and do not require systemic steroids for management of symptoms from CNS metastatic lesions). Any patients with documented brain metastasis not meeting above criteria for stab
Conditions Locally Advanced Triple Negative Breast ...
Phase EARLY_PHASE1
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Pilot trial of the IL-4 receptor antagonist dupilumab plus pembrolizumab, paclitaxel, and carboplatin in locally advanced triple negative breast cancer (TNBC). Primary Objective: To assess the safety of neoadjuvant dupilumab and pembrolizumab plus weekly paclitaxel and carboplatin as measured by the proportion of severe immune-related adverse events (irAEs) in patients with locally advanced TNBC. Secondary Objectives: To determine the rates of pathologic complete response with the addition of dupilumab to NAC and pembrolizumab; to determine the rate of residual cancer burden 0-1; to estimate the recurrence-free survival and overall survival; to assess the toxicity of the combination of dupilumab, pembrolizumab, and paclitaxel-carboplatin.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dupilumab — Dupilumab 600mg subcutaneous initial loading dose, 300mg for subsequent doses; administered every 3 weeks for 4 cycles. Immunotherapy drug FDA approved to treat patients with eczema, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Investigational/not yet FDA approved to treat patients with breast cancer.
  • Drug: Pembrolizumab — Pembrolizumab 200mg intravenous every 3 weeks for 4 cycles and one 400mg intravenous dose one week following completion of chemotherapy. Cancer immunotherapy drug FDA approved for the treatment of high-risk, early-stage, triple-negative breast cancer (TNBC).
  • Drug: Paclitaxel — Paclitaxel 80mg/m2 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
  • Drug: Carboplatin — Carboplatin AUC 1.5 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.

Primary Outcomes

  • Incidence of severe immune-related adverse events (irSAE) (Within 4 months of therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-03-05
Completion: 2027-03-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rima Patel
Principal Investigators:
  • Rima Patel, MD (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
  • Joseph Sparano, MD (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
Rima Patel, MD
(212) 604-6010
Rima.Patel2@mssm.edu
Katherine Vandris
Katherine.Vandris@mssm.edu
Katherine Vandris
Katherine.Vandris@mssm.edu
Mount Sinai Health System
Interventions
  • Drug: Dupilumab — Dupilumab 600mg subcutaneous initial loading dose, 300mg for subsequent doses; administered every 3 weeks for 4 cycles. Immunotherapy drug FDA approved to treat patients with eczema, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Investigational/not yet FDA approved to treat patients with breast cancer.
  • Drug: Pembrolizumab — Pembrolizumab 200mg intravenous every 3 weeks for 4 cycles and one 400mg intravenous dose one week following completion of chemotherapy. Cancer immunotherapy drug FDA approved for the treatment of high-risk, early-stage, triple-negative breast cancer (TNBC).
  • Drug: Paclitaxel — Paclitaxel 80mg/m2 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
  • Drug: Carboplatin — Carboplatin AUC 1.5 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
Study Locations (1 sites)
Mount Sinai Health System, New York, New York 10029 United States
Eligibility Criteria
Inclusion Criteria: * Patients with pathologically confirmed diagnosis of triple negative breast cancer, as defined by the most recent ASCO/CAP guidelines. * Patients must have previously untreated, localized TNBC with either tumor size ≥ 2 centimeters (T2-4N0) or lymph node involvement with at least a 1cm tumor (T1c-T4N1-3). * Patients must have previously untreated disease with no prior definitive breast surgery, radiation therapy, or systemic chemotherapy with therapeutic intent for this breast cancer. * Patients must be eligible to receive chemotherapy agents in the study including paclitaxel and carboplatin. * Patients must be willing and able to provide blood samples at the time points indicated in the study calendar. * Patients must be willing and able to have core needle biopsies of tumor prior to initiation of treatment. Should patients undergo pre-treatment or on-treatment biopsy procedure and inadequate number of biopsies are obtained, they may proceed with initiation/continuation of treatment at the discretion of the investigator and treating physician. * Age ≥ 18 years. * ECOG performance status 0-1. * Adequate organ and marrow function as defined below: * absolute neutrophil count ≥ 1,500/mcL * platelets ≥ 100,000/mcl * total bilirubin within normal institutional limits * AST(SGOT)/ALT(SPGT) ≤ 2.5 X institutional upper limit of normal * creatinine within normal institutional limits * Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or any treatment with therapeutic intent for the breast cancer. * Patients may not be receiving any other investigational agents. * Patients who have any distant metastases and considered to have Stage IV disease. * Patients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Patients on chronic steroids (more than 4 weeks at stable dose) equivalent to ≤ 10mg prednisone will not be excluded. * Patients with active autoimmune disease that has required systemic treatment in the past 1 year (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is acceptable. * History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel, dupilumab or pembrolizumab used in study. Documented allergic or hypersensitivity response to any protein therapeutics (e.g., recombinant proteins, vaccines, intravenous immune globulins, monoclonal antibodies, receptor traps). * HIV positive with detectable viral load, or anyone not on stable anti-viral (HAART) regimen, or with \<350 CD4+ T cells/microliter in the peripheral blood. * Known active Hepatitis B (e.g., HBV detected by PCR or active Hepatitis C (e.g., HCV RNA \[qualitative\] is detected). Patients with hepatitis B (HepBsAg+) who have controlled infection (serum hepatitis B virus DNA PCR that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study drug. * Known, untreated helminth infections. Patients with prior history of a helminth infection who were fully treated are permitted. * History of allogeneic hematopoietic cell transplantation or solid organ transplantation. * Receipt of a live vaccine within 30 days of planned start of study medication. * History of irAE in response to prior immunotherapy that has not improved to a Grade 0 or 1; this does not include chronic conditions such as endocrinopathies which can be treated with hormone replacement therapy. * History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis attributed to prior use of cancer immunotherapy that required immune-suppressive doses of glucocorticoids to assist with management. History of radiation pneumonitis treated with glucocorticoids. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
Conditions Early-Stage Breast Cancer, Neoadjuvant T...
Phase Not Applicable
Enrollment 2000
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients. The major goal is to provide a framework for genomic profiling, which serves as infrastructure for systematic biomarker-screening and -stratification for concise therapy-arm allocation in the interventional clinical phase II trial COGNITION-GUIDE (NCT05332561). In patients, who display a poor response to standard-of-care neoadjuvant chemotherapy, tissue samples before and after neoadjuvant therapy are subjected together with blood samples to comprehensive genomic profiling to identify patients potentially benefiting from biomarker-guided interventions in COGNITION-GUIDE. Samples not required for standard-of-care clinical procedures or genomic profiling are systematically collected in a dedicated bio-repository to fuel translational scientific companion programs. The continuously growing comprehensive database serves as an integrative resource for systematic, prospective multidimensional data collection (clinical records, biomaterial, genomic data). In summary, the overarching goal is to generate a precision oncology platform i) to identify clinically-actionable biomarkers and drug targets that drive genomics-guided therapies and ii) to couple the observational, diagnostic registry platform to the independent, biomarker-stratified clinical therapy trial COGNITION-GUIDE.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Genomic Profiling / Sequencing — Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy

Primary Outcomes

  • Comprehensive assessment of clinical patient data, collection of biomaterial and implementation of genomics- / molecular- and immune- guided precision medicine in eBC into the clinics. (31/12/2028)
  • Setting up a clinical and multidimensional, molecular diagnostic registry platform for patients with eBC and high risk for relapse. (31/12/2028)
  • Assessment of feasibility and retrieval of the logistical, clinical and information basis to screen and enroll patients for independent molecular-driven intervention trials (independent of this registry, e.g. COGNITION-GUIDE). (31/12/2028)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-04-19
Completion: 2028-12-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: German Cancer Research Center
Collaborators: University Hospital Heidelberg, German Federal Ministry of Education and Research
Principal Investigators:
  • Peter Lichter, PhD (PRINCIPAL_INVESTIGATOR) - German Cancer Research Center (DKFZ) Heidelberg
  • Andreas Schneeweiss, MD (PRINCIPAL_INVESTIGATOR) - National Center for Tumor Diseases, Heidelberg
  • Verena Thewes, PhD (PRINCIPAL_INVESTIGATOR) - National Center for Tumor Diseases, Heidelberg
Contact Information
Study Contact:
Andreas Schneeweiss, MD
0049-6221-5636051
Andreas.Schneeweiss@med.uni-heidelberg.de
Peter Lichter, PhD
0049-6221-424619
Peter.Lichter@Dkfz-Heidelberg.de
Nina Ditsch, MD
University Hospital Augsburg
Interventions
  • Other: Genomic Profiling / Sequencing — Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
Study Locations (12 sites)
University Hospital Augsburg, Augsburg, Germany
Charité - Berlin, Berlin, Germany
University Hospital Köln, Cologne, Germany
Medical Faculty and University Hospital Carl Gustav Carus, Dresden, Germany
University Hospital Erlangen, Erlangen, Germany
University Hospital Essen, Essen, Germany
National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany
Caritas Hospital St. Josef, Regensburg, Germany
Robert Bosch Hospital Stuttgart, Stuttgart, Germany
University Hospital Tübingen, Tübingen, Germany
Eligibility Criteria
Inclusion Criteria: * Female and male breast cancer patients aged ≥18 years. * Patients with primary early breast cancer (irrespective of subtypes) or - as an exception - patients with isolated loco-regional relapses that can be treated with a curative intention * Study entry is possible for patients with primary eBC at three timepoints: * Option A: patients planned to receive neoadjuvant chemotherapy are enrolled before starting the neoadjuvant treatment * Option B: patients with clinical non-complete response can be enrolled after the last cycle of neoadjuvant chemotherapy before surgery Note: Option A/B are strongly preferred entry time-points * Option C: eBC patients after surgery and planned or conducting standard-of-care (SoC) post-neoadjuvant chemotherapy can be enrolled after surgery until the last cycle of standard post-neoadjuvant chemotherapy, if they fulfill the following criteria * HER2+ BC or TNBC: non-pCR * HR+/HER2- BC: non-pCR and CPS-EG score ≥ 3 or non-pCR, ypN+ and CPS-EG-score ≥ 2 Note: Option C is not the preferred entry time-point Note: in case of loco-regional relapse, neoadjuvant treatment is not mandatory * Patients must be willing to donate a recent tumour sample to the registry Note: fresh tumour tissue is preferred * Patients, who agreed to and were able to sign the informed consent form (ICF). Exclusion Criteria: * Patients who did not sign or withdrew the informed consent form (ICF). * Inability to retrieve tissue for molecular profiling Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.
Conditions Breast Cancer
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

RATIONALE: Radiotherapy (RT) can be indicated to patients submitted to breast-conserving surgery, but, despite the benefits, adjuvant RT can cause contracture generated by tissue fibrosis in patients with immediate prosthetic reconstruction, which could cause prosthesis loss. The biological explanation of this outcome is not fully understood, but recent advances in the analysis of patient-derived blood can contribute to establishing a connection of molecular alterations related to this clinical outcome. There is not a consensus about using hypofractionated RT schemes for patients with BCS and breast reconstruction since no studies had investigated the reasons why some patients lose the prosthesis. PURPOSE: This study will evaluate G3 toxicity rate in breast cancer patients with immediate prosthetic reconstruction, submitted to hypofractionated radiotherapy, analyzing capsular contracture, leakage, infection, and bad positioning in order to demonstrate the noninferiority of Hypo-RT with the conventional RT. Additionally, the molecular profile of blood samples will be investigated in order to find biomarkers related to inflammations processes and response to treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Hypofractionation — Hypofractionation scheme will comprise 40 Gy in 15 fractions

Primary Outcomes

  • Assess the G3 toxicity rate (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-06-27
Completion: 2029-05-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Barretos Cancer Hospital
Principal Investigators:
  • Marcos D Mattos, MD, MS (PRINCIPAL_INVESTIGATOR) - Barretos Cancer Hospital
  • Gabriela B Salvador, BS (STUDY_CHAIR) - Barretos Cancer Hospital
  • Wanessa F Altei, PhD (STUDY_CHAIR) - Barretos Cancer Hospital
Contact Information
Study Contact:
Marcos D Mattos, MD, MS
+5517981140230
marcosbtos3@gmail.com
Alexandre A Jacinto, MD, PhD
+5517974001314
jacintoaa@gmail.com
Marcos D Mattos, MD, MS
+5517981140230
marcosbtos3@gmail.com
Radiation Oncology Department
Interventions
  • Radiation: Hypofractionation — Hypofractionation scheme will comprise 40 Gy in 15 fractions
Study Locations (1 sites)
Radiation Oncology Department, Barretos, São Paulo 14784-400 Brazil
Eligibility Criteria
Inclusion Criteria: * Women with confirmed histological diagnosis of invasive ductal carcinoma and lobular breast carcinoma; * Radical mastectomy with immediate reconstruction with a prosthesis; * Patients indicated for adjuvant RT; * Any lymph node status; * With or without adjuvant chemotherapy; * ECOG performance status from 0-2; * \> 18 years old; * Informed Consent Form applied before any study-specific procedure. Exclusion Criteria: * Another histological diagnosis than invasive ductal carcinoma or lobular carcinoma; * Previous history of neoplasm and/or radiotherapy and/ or quimiotherapy before this study; * Distant metastatic disease; * Palliative treatment; * Patients with scleroderma / systemic lupus erythematosus.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The primary goal of this observational study is to describe the distribution of treatment options and patients' characteristics according to the definition of high-risk status in the early breast cancer (EBC) setting. Participants already taking intervention as part of their regular medical care for EBC will answer questionnaires to also assess quality of life and patient reported outcomes. The recruitment phase will last about 2 years, each patient will be followed up for 5 years.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Drug: abemaciclib, olaparib and endocrine therapy — Patients receiving abemaciclib, olaparib and endocrine therapy.

Primary Outcomes

  • Distribution of treatment options (From enrollment to the end of treatment at 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-26
Completion: 2031-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Azienda Ospedaliero-Universitaria di Modena
Contact Information
Study Contact:
Luca Moscetti, MD
+ 39.059.422.3244
moscetti.luca@aou.mo.it
Luca Moscetti, MD
0594223244
moscetti.luca@aou.mo.it
Azienda Ospedaliero Universitaria Policlinico di Modena
Luca Moscetti, MD
Azienda Ospedaliero Universitaria Policlinico di Modena
Interventions
  • Drug: abemaciclib, olaparib and endocrine therapy — Patients receiving abemaciclib, olaparib and endocrine therapy.
Study Locations (1 sites)
Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Modena 41124 Italy
Eligibility Criteria
Inclusion Criteria: * Patients will be enrolled in the study if they meet all of the following inclusion criteria: * Age ≥ 18 years * Endocrine sensitivity defined as estrogen and or progesterone receptors expression as per local pathological standards * Her 2 negativity determined as ASCO/CAP guidelines * Patients receiving abemaciclib, olaparib and endocrine therapy, as per Italian drugs agency rules (AIFA) * Written informed consent, signed and dated by the patients * High-risk HR positive, Her2 negative early breast cancer patients with one of the following characteristics: * Anatomical stage IIA N0 with: * Grade 2 and evidence of high risk: * Ki-67 ≥ 20% * Oncotype DX Breast Recurrence Score ≥ 26 or High risk via genomic risk profiling * Grade 3 * Anatomical stage IIB. * Pathological tumour involvement in ≥4 ipsilateral axillary lymph nodes. * Pathological tumour involvement in 1 to 3 ipsilateral axillary lymph node(s) (for patients who received neoadjuvant therapy also cytological tumour involvement at time of initial diagnosis is allowed) and meet at least 1 of the following criteria: * Grade 3 as defined by a combined score of at least 8 points per the modified Bloom-Richardson grading system (Elston and Ellis 1991), * Pathological primary invasive tumour size ≥5 cm (for patients who received neoadjuvant therapy primary tumour size ≥5 cm on breast imaging is allowed). Note: if tumour size is needed to meet eligibility criteria, patients with multifocal/multicentric tumours may be eligible based on the addition of diameters of the individual lesions. BRCA mutated populations Patients must be node positive and fulfil one of the following criteria: * HR positive, HER2-negative patients must have had ≥4 pathologically confirmed positive lymph nodes * patients who received prior neoadjuvant chemotherapy: must have had a CPS\&EG score of ≥3 based on pre-treatment clinical and post-treatment pathologic stage (CPS), estrogen receptor (ER) status and histologic grade Exclusion Criteria: * Patients unable to understand the reason for their participation in the study, lack of informed written consent, * patients who do not meet the high risk criteria as specified in the inclusion criteria, * patients suffering from other neoplasms for which they receive active treatment, or being diagnosed with other neoplasms (except for: Carcinoma in situ (CIS) of the cervix, CIS of the colon, basal cell and squamous cell carcinomas of the skin) in the five years before adjuvant treatment.
Conditions Triple Negative Breast Cancer, Renal Cel...
Phase PHASE1, PHASE2
Enrollment 168
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1 Moditope vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab with or without Ipilimumab (where these are standard of care in a non-neoadjuvant setting), in patients with advanced triple negative breast cancer (TNBC), advanced/unresectable human papillomavirus-negative squamous cell carcinoma of the head and neck (SCCHN), high grade serous ovarian carcinoma (HGSOC), or renal cell carcinoma (RCC). Modi-1 Moditope will also be investigated in the neoadjuvant setting for patients with SCCHN undergoing curative intent surgical resection in combination with pembrolizumab versus the Modi-1 alone.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Modi-1 Moditope — Modi-1 Moditope administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
  • Biological: Pembrolizumab — Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
  • Device: MicronJet600™ microneedle device (NanoPass) — Intradermal injection device

Primary Outcomes

  • Incidence of clinical and laboratory adverse events (AEs) (For the duration of the study (12 weeks after the final dose of study treatment))
  • Cellular immune response to Modi-1 Moditope on IFNγ ELISpot assay (For the duration of the study (12 weeks after the final dose of study treatment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2022-04-07
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 168 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Scancell Ltd
Principal Investigators:
  • Christian Ottensmeier, MD (PRINCIPAL_INVESTIGATOR) - The Clatterbridge Cancer Centre NHS Foundation Trust, United Kingdom
Contact Information
Study Contact:
Robert Miller
+441865582690
info@scancell.co.uk
Joe Thornton
info@scancell.co.uk
Velindre Cancer Centre
Joe Thornton
info@scancell.co.uk
Edinburgh Cancer Centre (NHS Lothian)
Interventions
  • Biological: Modi-1 Moditope — Modi-1 Moditope administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
  • Biological: Pembrolizumab — Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
  • Device: MicronJet600™ microneedle device (NanoPass) — Intradermal injection device
Study Locations (16 sites)
Brighton and Sussex University Hospital, Brighton, Default United Kingdom
Velindre Cancer Centre, Cardiff, Default United Kingdom
Edinburgh Cancer Centre (NHS Lothian), Edinburgh, Default United Kingdom
Royal Surrey NHS Foundation, Guildford, Default United Kingdom
Imperial College Healthcare NHS Trust, London, Default United Kingdom
Mount Vernon, London, Default United Kingdom
University College London Hospital NHS Foundation Trust, London, Default United Kingdom
Christie NHS Foundation Trust, Manchester, Default United Kingdom
Nottingham University Hospitals Cancer Centre, Nottingham, Default United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Default United Kingdom
Eligibility Criteria
INCLUSION CRITERIA 1. Patient either has one of the following histologically or cytologically confirmed advanced cancers not amenable to curative intent surgical resection: * TNBC * SCCHN (oral cavity, oropharynx, hypopharynx, or larynx) * HGSOC including fallopian tube and primary peritoneal cancers * RCC Or the patient has histologically or cytologically confirmed SCCHN scheduled to have curative intent surgical resection. 2. Patient must meet one of the following specific criteria for prior treatment of the relevant tumour type: * TNBC: * patient has received available standard therapy for advanced disease (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient stopped immunotherapy due to toxicity and with residual disease as measurable by RECIST 1.1 (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient completing a systemic treatment regimen with immunotherapy, for whom a subsequent SOC therapy is not yet indicated or appropriate and with measurable disease in accordance with RECIST 1.1 (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient has refused SOC therapy (Modi-1ev/Modi-1eKv monotherapy cohort only). * SCCHN: * patient has received first-line platinum-containing chemotherapy (with or without radiotherapy) as treatment for advanced disease (Modi-1ev/Modi-1eKv monotherapy and Modi-1ev/Modi-1eKv + CPI cohorts). * patient with locally advanced or metastatic disease measurable by RECIST 1.1 for whom all forms of platinum-based chemoradiotherapy treatment are contraindicated (Modi-1ev/Modi-1eKv monotherapy and Modi-1ev/Modi-1eKv + CPI cohorts). * patient completing immunotherapy for whom a subsequent SOC therapy is not yet indicated or appropriate and with measurable disease in accordance with RECIST 1.1 (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient stopped immunotherapy due to toxicity or completion of immunotherapy but with measurable disease in accordance with RECIST 1.1 (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient with untreated metastatic or unresectable recurrent SCCHN whose tumours express PD-L1 with a combined positive score (CPS) of one or more and are eligible for SOC immunotherapy (Modi-1ev/Modi-1eKv + CPI cohort only). Patients who received their first dose of CPI therapy within 28 days of the first dose of Modi-1ev/Modi-1eKv are eligible. * patient has refused SOC therapy (Modi-1ev/Modi-1eKv monotherapy cohort only). * SCCHN: o neoadjuvant expansion cohort only; patients who are treatment-naïve and are scheduled to have tumour resection surgery, in whom minimum of 3 weeks of Modi-1ev/Modi-1eKv and a single 400 mg intravenous (i.v.) total dose of pembrolizumab immunotherapy can be administered. Patients will only be enrolled once the Modi-1 Moditope® expansion doses and a lack of increased anti-CCP antibodies (with, and without, concomitant pembrolizumab) have been established. * HGSOC including fallopian tube and primary peritoneal cancers: * patient must be considered unsuitable for platinum chemotherapy, defined as recurrence/progression within 6 months of prior platinum-containing chemotherapy or patients in whom platinum therapy is no longer thought appropriate. Patient must have received no more than two non-platinum regimens, from the time the patient is considered unsuitable for platinum chemotherapy (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient completing a course of systemic therapy for whom a subsequent SOC therapy is not yet indicated or appropriate and with measurable disease in accordance with RECIST 1.1 (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient has refused SOC therapy (Modi-1ev/Modi-1eKv monotherapy cohort only). * RCC: * patient is untreated for advanced RCC (Modi-1ev/Modi-1eKv + CPI doublet cohort only). * patient has received first-line treatment consisting of anti-angiogenic therapy (Modi-1ev/Modi-1eKv monotherapy cohort). * patient has favourable or intermediate International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) risk score (Heng et al. 2013) (Modi-1ev/Modi-1eKv monotherapy cohort). * patient has intermediate or poor International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) risk score (Heng et al. 2013) and is eligible for SOC nivolumab with ipilimumab immunotherapy (Modi-1ev/Modi-1eKv + CPI doublet cohort only). * patient has stopped immunotherapy due to toxicity and with residual disease as measurable by RECIST 1.1 (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient completing immunotherapy, for whom a subsequent SOC therapy is not yet indicated or appropriate and with measurable disease in accordance with RECIST 1.1 (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient on active surveillance (Modi-1ev/Modi-1eKv monotherapy cohort only). * patient is eligible for SOC nivolumab with ipilimumab immunotherapy (Modi-1ev/Modi-1eKv + CPI doublet cohort only). * patient has refused SOC therapy (Modi-1ev/Modi-1eKv monotherapy cohort only). 3. Where applicable, patient has completed last dose of prior cancer therapy at least 4 weeks before the first dose of study treatment. 4. Patient has been fully vaccinated against COVID-19, the last vaccination being at least 14 days prior to the patient's first dose of IMP, except for those who have declined or are not eligible for COVID-19 vaccination. 5. Patient has recovered to Grade ≤1 (CTCAE v5.0) from the effects (excluding alopecia) of any prior therapy for their malignancies. 6. Patient has at least one measurable lesion per RECIST 1.1 criteria by computed tomography (CT) scan or magnetic resonance imaging (MRI) (non-neoadjuvant cohorts). 7. Wherever possible, patients not scheduled for curative intent resection surgery should have a fresh tumour biopsy (or have an archival biopsy \[obtained within the past 5 years\] if obtaining a fresh biopsy is not feasible) at baseline for molecular studies, and agree to a post-treatment biopsy (at Week 25 or one of the EOT visits), if feasible. Patients in the SCCHN neoadjuvant cohort must have both a fresh pre-treatment biopsy and agree to have their resected tumour analysed. 8. Patient is male or female and at least 18 years of age. 9. Patient has a life expectancy of more than 6 months. 10. Patient has an ECOG performance status of 0 or 1. 11. Patient has adequate organ function as determined by the following laboratory values: absolute neutrophil count ≥1.5 x 109/L, platelets ≥100 x 109/L, haemoglobin \>90 g/L (\>5.6 mmol/L), lymphocytes ≥ 1 x 109/L, serum creatinine ≤1.5 x upper limit of the normal range (ULN), serum total bilirubin ≤1.5 x ULN, serum transaminases (aspartate aminotransferase \[AST\]/alanine aminotransferase \[ALT\]) ≤2.5 x ULN or ≤5.0 x ULN if liver metastases present. 12. Patient must be able and willing to provide written informed consent prior to any study related procedure. (In the event that the patient is re-screened for study participation or if a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed). 13. Women of child-bearing potential must have a negative serum pregnancy test during Screening (and a urine test within the 7 days prior to Day 1) and be neither breastfeeding nor intending to become pregnant during study participation. Women of child-bearing potential must agree to use highly effective contraceptive methods prior to study entry, for the duration of study participation, and for 120 days after discontinuation of vaccine monotherapy or 5 months after use with a CPI (or longer if the Summary of Product Characteristics \[SmPC\] of the CPI requires it). 14. Men who are potentially fertile with partners of child-bearing potential must agree to use highly effective contraceptive methods for the duration of study participation, and for 120 days after discontinuation of vaccine monotherapy or 5 months after use wit
Conditions Cancer-related Fatigue, Breast Cancer, L...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Cancer-related fatigue is one of the most common and distressing symptoms experienced by patients during and after cancer treatment, and current options to manage it are limited. Guaraná (Paullinia cupana), an Amazonian plant rich in caffeine and other methylxanthines with anti-inflammatory and central-nervous-system-stimulating properties, has shown preliminary benefit for fatigue in small studies but lacks robust evidence. This pragmatic, prospective, single-arm study will evaluate whether guaraná supplementation reduces chronic cancer-related fatigue and improves quality of life in 60 patients with breast, lung, colorectal, or gastric cancer receiving active systemic treatment. Participants will take a 50 mg guaraná capsule by mouth every 12 hours for up to six 21-day cycles. The main outcome is the change in fatigue (baseline vs. post-intervention) measured with the FACIT-F and the Brief Fatigue Inventory (BFI). Secondary outcomes include quality of life (EORTC QLQ-C30) and adverse events. The study aims to support guaraná as a safe, accessible complementary option in supportive cancer care.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Dietary Supplement: Guaraná (Paullinia cupana) — Guaraná 50 mg capsule administered orally every 12 hours, 21 days per cycle, for up to 6 cycles (total 126 days). Manufactured by INVIMA-certified suppliers; stored under controlled conditions. Adherence monitored by capsule count plus patient diary; adverse events graded with CTCAE v5.0.

Primary Outcomes

  • Change in cancer-related fatigue measured by FACIT-F (Functional Assessment of Chronic Illness Therapy - Fatigue) (Baseline, week 3, and end of treatment (up to 126 days))
  • Change in fatigue measured by the Brief Fatigue Inventory (BFI) (Baseline, week 3, and end of treatment (up to 126 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-20
Completion: 2027-06-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Principal Investigators:
  • Andrés F Cardona, MD, MSc, PhD, MBA (STUDY_DIRECTOR) - Fundación CTIC Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
Contact Information
Study Contact:
Liliana Gutiérrez, RN, MSc
+573003768158
lgutierrez@fctic.org
Briegel De Las Salas, Microb, MSc
+573044921963
bcalderon@fctic.org
Liliana Gutiérrez, RN, MSc
+573003768158
lgutierrez@fctic.org
Fundación CTIC Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
Interventions
  • Dietary Supplement: Guaraná (Paullinia cupana) — Guaraná 50 mg capsule administered orally every 12 hours, 21 days per cycle, for up to 6 cycles (total 126 days). Manufactured by INVIMA-certified suppliers; stored under controlled conditions. Adherence monitored by capsule count plus patient diary; adverse events graded with CTCAE v5.0.
Study Locations (1 sites)
Fundación CTIC Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Bogota D.C. 110131 Colombia
Eligibility Criteria
Inclusion Criteria: * Histologic diagnosis of breast, lung, colorectal, cervical or gastric cancer * Receiving active cancer treatment * Has completed at least three cycles of chemotherapy Exclusion Criteria: * Intolerance to the oral route * Contraindications to guaraná intake * Uncontrolled cardiovascular disease (uncontrolled atrial fibrillation, symptomatic tachyarrhythmias, prolonged QT) * History of intolerance to caffeine, methylxanthines, or flavonoids * Use of CNS stimulants * Recent history of bleeding * Use of warfarin or any other vitamin K antagonist * Use of theophylline
Conditions Advanced Solid Tumor Cancer
Phase PHASE1
Enrollment 52
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to establish the safety of X-PACT when dosed with 5 intra-tumoral injections of the combination product (the phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) over a period of 6 weeks (on day D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6). After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligible to receive two additional booster treatments 4-6 weeks apart. Treatment will be considered safe provided ≤ 2 out of 12 patients experience a dose-limiting toxicity (DLT) during the 6 weeks after the first intra-tumoral injection. Two expansion cohorts have been added to the study. One for TNBC and one for soft tissue sarcoma. 16 additional subjects will be added in each of the expansion cohorts.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Combination Product: X-PACT — X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.

Primary Outcomes

  • Dose-Limiting Toxicity (DLT) (First 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2021-12-08
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Immunolight, LLC
Principal Investigators:
  • William Eward, MD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Susan N McLaughlin, BSN
7048776363
smclaughlin@immunolight.com
Lauren Wood, MD
6788995225
Panagis Galiatsatos, MD
Sibley Hospital - Johns Hopkins University
Interventions
  • Combination Product: X-PACT — X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
Study Locations (4 sites)
Sibley Hospital - Johns Hopkins University, Washington D.C., District of Columbia 20016 United States
Levine Cancer Institute, Charlotte, North Carolina 28204 United States
Duke University, Durham, North Carolina 27710 United States
Prisma Health, Greenville, South Carolina 29605 United States
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 2. Age ≥ 18 years at the time of consent 3. ECOG Performance Status of ≤ 1 4. Subjects with histologically or cytologically confirmed advanced solid tumors which have progressed after standard therapy(ies), intolerant to standard therapy, refused standard therapy or for which no standard therapy(ies) exist. Furthermore, the tumor targeted for injections should be: 1. A non-visceral tumor, a metastatic lymph node, a metastasis from a visceral solid tumor provided the lesion is extravisceral, or a cutaneous tumor. Visceral tumors will not be treated. 2. The tumor must be measurable as per RECIST criteria. 3. The tumor should be directly accessible for injection or accessible with the use of ultrasound/CT guidance. 4. The tumor identified for injection should be selected so local control could potentially provide benefit to the patient. 5. 80% of the tumor must be accessible for injection with X-PACT (assessed by the treating physician) 6. The tumor must be superficial and not exceed a depth of 5 cm. 7. Eye or brain tumors will not be treated. 5. A patient with prior brain metastasis may be considered if they have completed their treatment for brain metastasis at least 4 weeks prior to day 1 of treatment, have been off of corticosteroids for ≥ 2 weeks, and brain metastases are asymptomatic. 6. The study site Radiation Oncologist Investigator/sub-investigator has determined additiional radiation delivered via X-PACT is appropriate given patient's prior radiation exposure. The treating Radiation Oncologist will review all prior radiation received to the proposed site of X-PACT treatment and assess the potential for unacceptable toxicity to the site or local organ(s) using QUANTEC. 7. All toxicities from prior therapy should be ≤Grade 1 before start of study treatment. All radiation associated toxicities must have completely resolved to be considered for inclusion into the study. 8. Demonstrate adequate organ function as defined in the table below: Hematological: White blood cell (WBC) ≥ 3 x 109/L Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L Platelet Count ≥ 100 x 109/L Hemoglobin (Hgb) ≥ 8 g/dL2 Renal: Serum creatinine OR Creatinine clearance ≤ 1.5 x upper limit of normal (ULN) OR, in patients with a serum creatinine 1.5 x ULN, ≥ 60 mL/min as measured by a 24-hour urine collection or estimated by the Cockcroft and Gault formula Hepatic: Total bilirubin ≤ 1.5 × ULN (in patients with known Gilbert Syndrome a total bilirubin ≤3.0× ULN with direct bilirubin ≤1.5 X ULN) Aspartate aminotransferase (AST) ≤ 2.5 × ULN (or ≤ 5 if liver metastases are present) Alanine aminotransferase (ALT) ≤ 2.5 × ULN (or ≤ 5 if liver metastases are present) Coagulation: International Normalized Ratio (INR) ≤ 1.5 9. Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 3 days prior to day 1 of treatment. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause). 10. FCBP must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of \<1% per year when used consistently and correctly) from the time of informed consent until 28 days after treatment discontinuation. Contraceptive methods with low user dependency are preferable but not required (see table below, adapted from: http://www.hma.eu/fileadmin/dateien/Human\_Medicines/01-About\_HMA/Working\_Groups/CTFG/2014\_09\_HMA\_CTFG\_Contraception.pdf) Highly Effective Birth Control Methods: * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation o oral * intravaginal * transdermal * progestogen-only hormonal contraception associated with inhibition of ovulation o oral * injectable * implantable * intrauterine device (IUD) * intrauterine hormone-releasing system (IUS) * vasectomised partner * sexual abstinence 11\. Male patients must be willing to use condoms from the time of informed consent until 28 days after treatment discontinuation. For a non-pregnant FCBP partner, contraception recommendations should also be considered. 12\. As determined by the enrolling physician, ability of the patient to understand and comply with study procedures for the entire length of the study 13\. Patient is expected to have a life expectancy of at least 4 months 14\. If the proposed site of treatment with X-PACT had prior exposure to curative-intent radiation, the patient may be entered into the trial with the following provisions satisfied. * There is at least a 6 month wash out period from the last date radiation was received to assess for radiation toxicity. * If there was previous radiation toxicity at the proposed site of X-PACT, the toxicity resolved at least three months ago and the site did not involve a major organ. * The site investigator in addition to the radiation oncologist (as a part of criterion #6) has fully reviewed the subject's radiation history, has examined the area for radiation toxicity and assessed the cumulative dose for either 5 or 7 X-PACT treatments and determined they will not pose additional risk for radiation toxicity or re-activate any other previous toxicity. Exclusion Criteria: * Exclusion Criteria: 1. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study.) 2. Prior exposure to methoxsalen 3. History of any of the following: a. Idiosyncratic or hypersensitivity reactions to any psoralen compounds or any of their excipients b. Light sensitive disease state c. Disease associated with photosensitivity including lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum and albinism d. Aphakia 4. History of idiosyncratic or hypersensitivity reactions to any of the phosphor device components 5. Known diagnosis of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection (NOTE: testing not required) 6. Active infection requiring systemic therapy (NOTE: at discretion of investigator, patients with uncomplicated urinary tract infections may be eligible.) 7. Has a known additional other primary malignancy that is active and/or progressive requiring treatment; exceptions include basal cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the patient has been disease-free for at least five years. 8. Systemic anti-cancer treatment within 28 days (or 5 half-lives, whichever is shorter) prior to day 1 of treatment 9. Treatment with any investigational drug within 5 half-lives or 28 days, whichever is shorter (or if half-life is unknown, within 28 days) prior to day 1 of treatment 10. Impaired cardiac function or clinically significant cardiac diseases, including any of the following: a. Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded) b. Uncontrolled hypertension (systolic BP \> 170 mmHg or diastolic BP \> 105 mmHg at screening) despite two concomitant antihypertensive therapies. c. Acute myocardial infarction or unstable angina ≤ 6 months prior to day 1 of treatment d. New York Heart Association Class III or IV congestive heart failure ( 11. Other uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator. 12. The tumor identified for treatment has
Conditions Breast Carcinoma, Genetic Predisposition...
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Cancer-free women with a hereditary predisposition to breast and/or ovarian cancer

Design

Study type: Observational Observational model: Family Based Time perspective: Prospective

Interventions / Regimen

  • Genetic: Mutation Burden cfMB analysis — Blood samples will be collected (one time only)

Primary Outcomes

  • Comparing the mutational burden in a person genetically predisposed to cancer with that of a non-predisposed relative (At the enrollment in the study (one point))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-04
Completion: 2027-12-30
Eligibility
Age: 30 Years – 50 Years
Sex: FEMALE
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Francois Baclesse
Contact Information
Study Contact:
Louise May THIBAUT, Medical Doctor
0231455050
lm.thibaut@baclesse.unicancer.fr
Louise May THIBAUT, MD
lm.thibaut@baclesse.unicancer.fr
Centre François Baclesse
Interventions
  • Genetic: Mutation Burden cfMB analysis — Blood samples will be collected (one time only)
Study Locations (1 sites)
Centre François Baclesse, Caen, France France
Eligibility Criteria
Inclusion Criteria: * Female participant * Participant undergoing oncogenetic follow-up at the Centre François Baclesse * Participant belonging to a pair of related biological siblings * Within the sibling pair, one participant is a carrier of a hereditary predisposition linked to a BRCA1/2 mutation (case), and the other participant is not a carrier (control). * Participant between 30 and 50 years of age * Participant affiliated to a social security scheme * Participant having given her consent to participate by signing an informed consent form prior to any specific study-related procedure. Exclusion Criteria: \-
Conditions Breast Cancer, Nipple Discharge
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, single-center diagnostic study testing whether a new, minimally invasive analysis of nipple fluid can distinguish benign from malignant causes of pathologic nipple discharge. Many patients with bloody or blood-tinged nipple discharge undergo surgery to make a diagnosis, yet most are ultimately found to have benign disease. The investigators aim to develop a laboratory test that analyzes DNA in nipple fluid to help avoid unnecessary operations while still identifying cancers. Approximately 30 adults with spontaneous, single-duct, unilateral bloody or serosanguinous nipple discharge who are already scheduled for standard diagnostic surgery will be enrolled at Hubei Cancer Hospital. Before surgery, the investigators will collect a small sample of nipple fluid (or gently obtain nipple aspirate fluid using a soft suction cup if needed) and one tube of blood. The investigators will analyze the fluid's DNA using two approaches: low-pass whole-genome analysis to look for copy number changes and fragmentation patterns, and genome-wide DNA methylation profiling. Surgical pathology will serve as the reference standard. Using these data, the investigators will build and validate a model to classify lesions as benign or malignant. The primary outcome is diagnostic accuracy (area under the ROC curve, sensitivity, and specificity). Secondary outcomes include positive and negative predictive values, model calibration, subgroup performance (e.g., ductal carcinoma in situ vs invasive cancer), and an estimate of potential clinical impact (for example, how many benign cases might safely avoid surgery at a high-sensitivity threshold). Study test results will not affect current clinical care; all participants will receive usual evaluation and surgery. Risks are minimal and may include brief nipple discomfort or skin irritation from gentle suction and routine blood-draw risks (bruising, lightheadedness). There is no direct benefit to participants, but the findings may support a future noninvasive test to guide care and reduce unnecessary surgery. Data will be de-identified and stored securely. Expected enrollment is from September 2025 to May 2026.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • AUC of the combined lcWGS-methylome model for distinguishing malignant vs benign lesions (From preoperative sampling to receipt of final surgical pathology (per participant); primary analysis at validation lock (≈0-3 months post-enrollment).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-21
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hubei Cancer Hospital
Contact Information
Study Contact:
Xinhong Wu Principal Investigator
+8618602726300
wuxinhong_9@sina.com
Interventions
N/A
Study Locations (1 sites)
Wu Xinhong, Wuhan, Hubei 430079 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years. 2. Spontaneous, unilateral, single-duct pathologic nipple discharge, predominantly bloody or serosanguinous, raising clinical suspicion of intraductal disease. 3. Planned diagnostic breast surgery/biopsy after specialist assessment (e.g., duct excision/microdochectomy, lumpectomy); patients who had ductoscopy but are still scheduled for surgery remain eligible. 4. Study sampling (nipple discharge and one peripheral blood tube) feasible before surgery/invasive diagnostics without delaying standard care. 5. Able and willing to provide written informed consent and allow access to surgical pathology and relevant clinical data. Exclusion Criteria: 1. Physiologic or non-pathologic discharge (typically bilateral, multiduct, expressible only with manipulation; milky/clear/green) or galactorrhea due to endocrine/drug causes. 2. Active breast infection/inflammatory disease (e.g., abscess) as the source of discharge. 3. Prior diagnosis and treatment of breast cancer (surgery/radiation/systemic therapy). 4. Recent invasive ductal manipulation likely to confound analysis (e.g., ductoscopy, duct cannulation/irrigation), per investigator judgment. 5. Pregnant or lactating patients. 6. Significant hematologic disease/coagulopathy precluding safe sampling. 7. Inability to complete preoperative study sampling, refusal/withdrawal of consent, or poor compliance. 8. Any condition judged by investigators to compromise sample quality, data interpretation, or participant safety.
Conditions Breast Cancer Awareness
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Prospective observational study evaluating the safety and accuracy of Feminai 1.0, an at-home adhesive patch that measures skin temperature and electrical impedance to map each breast. Up to 300 women (ages 25-75) undergoing screening will have one study visit; Feminai results will be compared with mammography and, when available, biopsy to assess sensitivity and negative predictive value. Feminai is investigational, intended to support clinical decision-making, and does not replace standard diagnostic tests.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Sensitivity and NPV (From enrollment to the time the the ground truth is available followed for up to 6 months)
  • Sensitivity and NPV (From enrollment to the time that the mammography and biopsy results (if applicable) are available followed for up to 6 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-05
Completion: 2026-09-05
Eligibility
Age: 25 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Feminai
Contact Information
Study Contact:
Jennifer Pantleo, RN BSN BBA CBCN
214-872-4484
Jennifer.Pantleo@solismammo.com
Solis Mammography Frisco at Stonebriar
Interventions
N/A
Study Locations (1 sites)
Solis Mammography Frisco at Stonebriar, Frisco, Texas 75034 United States
Eligibility Criteria
Inclusion Criteria: General: 1. Females aged 25-75 years. 2. Able to comply with study procedures and follow-up requirements. 3. Willing and able to provide informed consent. Additional for Group 1 (up to N=150): 1. Presenting for routine mammography/tomosynthesis breast cancer screening according to national/regional guidelines. 2. Most recent mammography result - BIRADS 1 or 2 Additional for Group 2 (up to N=150): 1\. Presenting for biopsy following BIRADS 4-5 mammogram Exclusion Criteria: 1. History of current treatment for breast cancer. 2. Pregnancy or lactation. 3. Presence of any implanted metal. 4. Any condition that, in the opinion of the investigator, may interfere with the participant's ability to comply with study requirements or may pose a risk to the participant. 5. Has breast enhancements (e.g. implants or injections) 6. Subjects who have undergone surgery (e.g. lumpectomy or mastectomy) in the last year at the time of study enrollment 7. No subject will be allowed to enroll in this trial more than once. 8. Cup size larger than E in US-based sizing charts.